Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

Shots:

  • The first patient has been dosed in a P-II study of TD-0903. The P-II study consists of two parts: the first part will assess the safety, tolerability, and clinical response to treatment in sequential ascending dose cohorts of hospitalized COVID-19 patients, with each patient demonstrating hypoxia being dosed for 7 days
  • The second part will be conducted at hospital-based clinical sites in the UK, EU & the US, pending appropriate Ethics Committee, and regulatory approvals in territories. The P-II study in the UK follows the completion of dosing in the P-I study in healthy volunteers
  • TD-0903 is a lung-selective, nebulized pan-JAK inhibitor, being developed to treat hospitalized patients with ALI caused by COVID-19

Click here to read full press release/ article | Ref: Theravance | Image: Theravance